SSY Group gets NMPA approval for two new chemical drugs

SSY Group Limited has received approval from the National Medical Products Administration of China (NMPA) for the production and registration of Acetylcysteine Injection (25ml: 5g). This type 3 chemical drug is considered to have passed consistency evaluation and marks the third such approval for the company's PRC entities. Acetylcysteine Injection is primarily used for detoxifying acute acetaminophen poisoning to mitigate hepatic injury.

Additionally, the Group secured NMPA approval for Compound Sodium Acetate Ringer's Injection (500ml). This drug, also a type 3 chemical drug, has been recognized as passing the consistency evaluation. It is mainly indicated for supplementing extracellular fluid and correcting metabolic acidosis in patients with reduced circulating blood volume and interstitial fluid.

These approvals represent an update on the company's product development, with the board comprising executive directors Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung, and Ms. Qu Wanrong, alongside a non-executive director and independent non-executive directors.